Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform

J Mol Diagn. 2020 Mar;22(3):368-375. doi: 10.1016/j.jmoldx.2019.11.005. Epub 2019 Dec 24.

Abstract

Clinical testing for MLH1 promoter hypermethylation status is important in the workup of patients with MLH1-deficient colorectal and uterine carcinomas when evaluating patients for Lynch syndrome. Current assays use single gene-based methods to assess promoter hypermethylation. Herein, we describe the development and report the performance of a clinical assay for MLH1 promoter hypermethylation using the Infinium methylationEPIC (850k) bead-array platform. Using four cytosine-guanine dinucleotide (CpG) sites within the MLH1 gene promoter, a qualitative MLH1 promoter hypermethylation assay was developed and validated using 63 gastrointestinal and uterine carcinoma samples of known hypermethylation status based on a pyrosequencing reference test. The array-based method achieves clinically robust and reproducible results at an analytical sensitivity level of 8%. Of importance, the 850k array contains probes targeting >850,000 additional CpG sites across the genome, covering sites in most known genes as well as important enhancer regions provided by the Encyclopedia of DNA Elements and Functional Annotation of The Mammalian Genome projects. Thus, the testing modality presented may also be applied to determine the methylation status of other clinically relevant genes or regulatory regions, potentially providing a single laboratory testing workflow for all clinical methylation assays. Furthermore, the concomitant acquisition of genome-wide methylation information provides a workflow that seamlessly enables wider translational epigenetic research.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • CpG Islands
  • DNA Methylation*
  • Epigenomics* / methods
  • Female
  • Genome-Wide Association Study* / methods
  • Genome-Wide Association Study* / standards
  • High-Throughput Nucleotide Sequencing* / methods
  • Humans
  • Male
  • MutL Protein Homolog 1 / genetics*
  • Promoter Regions, Genetic*
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • MLH1 protein, human
  • MutL Protein Homolog 1